Resistance to combination therapies has been reported in rhabdomyosarcoma (RMS). Here, the authors discover that PIK3CA/AKT pathway regulation of multidrug-resistant ABC transporters is involved in the resistance to therapies in RMS, and use of the PI3Kα inhibitor alpelisib re-sensitizes RMS to therapy.
- Qiqi Yang
- Yueyang Wang
- David M. Langenau